Home > Quotes > IMGN
IMGN

ImmunoGen, Inc. Common Stock Quote & Summary Data

$6.85
*  
1.60
18.93%
Get IMGN Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading IMGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

ImmunoGen, Inc. Common Stock Intraday Chart




Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 7.25 $ 19.43
Low $ 6.59 $ 6.77

The current last sale of $6.85 is 1.18% Higher thanthe 52 week low.

P/E Ratio

ETFs with IMGN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0% BioShares Biotechnology Clinical Trials Fund (BBC) -9.68 (-32.21%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We develop novel, targeted therapeutics for the treatment of cancer using our expertise in cancer biology, monoclonal antibodies, highly potent cytotoxic, or cell-killing, agents, and the design of linkers that enable these agents to be stably attached to the antibodies while in the blood stream and released in their fully active form after delivery to a cancer cell. An anticancer compound made using our Targeted Antibody Payload, or TAP, technology consists of a monoclonal antibody that binds specifically to an antigen target found on cancer cells with multiple copies of one of our proprietary cell-killing agents attached using one of our engineered linkers. Its antibody component enables a TAP compound to bind specifically to cancer cells that express a particular target antigen, the highly potent cytotoxic agent serves to kill the cancer cell, and the engineered linker controls the release and activation of the cytotoxic agent inside the cancer cell.  ... More ...  

Risk Grade

Where does IMGN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?